Factors that include patient demographic data, such as age and gender, IBC clinical data, such as tumor grade and NC response, histopathological data, such as lymph node metastasis and lymphovascular invasion, as well as immunohistochemistry data, such as staining of several other markers (ER, PR, HER2, and Ki67) were also examined. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.